Home > Drugs A-Z > NARS FOUNDATION

NARS FOUNDATION (NARS Cosmetics)

Available Formats

Dosage Form Package Information Links
POWDER 1 TRAY in 1 CARTON (13734-114-30) > 12 g in 1 TRAY Label Information

Complete NARS FOUNDATION Information

  • SPL UNCLASSIFIED SECTION

    Drug Facts


  • ACTIVE INGREDIENT

    Active ingredients Purpose
    OCTINOXATE 4.9% Sunscreen
    TITANIUM DIOXIDE 6.6% Sunscreen

  • Uses

    • helps prevent sunburn

  • Warnings

    Skin Cancer/Skin Aging Alert

    Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to prevent sunburn, not skin cancer or early skin aging.

    For external use only

    Do not use on damaged or broken skin

    When using this product keep out of eyes. Rinse with water to remove.

    Stop use and ask a doctor if rash occurs

    Keep out of reach of children. If product is swallowed, get medical help or contact a Poison Control Center right away.


  • Directions

    • apply liberally 15 minutes before sun exposure
    • use a water resistant sunscreen if swimming or sweating
    • reapply at least every 2 hours
    • children under 6 months: Ask a doctor

  • Inactive Ingredients

    NYLON-12 , CALCIUM STEARATE , SILICA , DIMETHICONE , JOJOBA ALCOHOL , ISOPROPYL JOJOBATE , JOJOBA ESTERS , HYDROGENATED LECITHIN , TRIMETHYLSILOXYSILICATE , LAUROYL LYSINE , METHICONE , SORBITAN SESQUIOLEATE , METHYLPARABEN , PROPYLPARABEN , BHT , TOCOPHEROL , [(MAY CONTAIN): MICA , TITANIUM DIOXIDE , IRON OXIDES , IRON OXIDES , IRON OXIDES] ,


  • Other information

    protect this product in this container from excessive heat and direct sun


  • Questions or comments?

    Call toll free 1-888-788-NARS


  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BARCELONA

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BARCELONA

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BENARES

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - BENARES

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - CÁDIZ

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - CÁDIZ

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - DEAUVILLE

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - DEAUVILLE

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - FIJI

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - FIJI

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - MONT BLANC

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - MONT BLANC

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - NEW ORLEANS

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - NEW ORLEANS

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - PUNJAB

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - PUNJAB

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SANTA FE

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SANTA FE

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SIBERIA

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SIBERIA

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - STROMBOLI

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - STROMBOLI

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SYRACUSE

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - SYRACUSE

  • PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - TAHOE

    NARS

    POWDER FOUNDATION BROAD SPECTRUM
    SPF 12 SUNSCREEN

    NET WT. 0.42 Oz. 12 g

    PRINCIPAL DISPLAY PANEL - 12 g Tray Carton - TAHOE

  • INGREDIENTS AND APPEARANCE
    NARS FOUNDATION   BARCELONA
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-114
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-114-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   BENARES
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-115
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-115-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   CADIZ
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-116
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-116-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   DEAUVILLE
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-117
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-117-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   FIJI
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-118
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-118-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   MONT BLANC
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-119
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-119-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   NEW ORLEANS
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-120
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-120-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   PUNJAB
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-121
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-121-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   SANTA FE
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-122
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-122-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   SIBERIA
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-123
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-123-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   STROMBOLI
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-124
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-124-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   SYRACUSE
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-125
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-125-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    NARS FOUNDATION   TAHOE
    octinoxate and titanium dioxide powder
    Product Information
    Product Type HUMAN OTC DRUG Item Code (Source) NDC:13734-126
    Route of Administration TOPICAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    OCTINOXATE (UNII: 4Y5P7MUD51) (OCTINOXATE - UNII:4Y5P7MUD51) OCTINOXATE 588 mg  in 12 g
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP) (TITANIUM DIOXIDE - UNII:15FIX9V2JP) TITANIUM DIOXIDE 792 mg  in 12 g
    Inactive Ingredients
    Ingredient Name Strength
    NYLON-12 (UNII: 446U8J075B)  
    CALCIUM STEARATE (UNII: 776XM7047L)  
    SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
    DIMETHICONE (UNII: 92RU3N3Y1O)  
    TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)  
    LAUROYL LYSINE (UNII: 113171Q70B)  
    METHICONE (20 CST) (UNII: 6777U11MKT)  
    SORBITAN SESQUIOLEATE (UNII: 0W8RRI5W5A)  
    METHYLPARABEN (UNII: A2I8C7HI9T)  
    PROPYLPARABEN (UNII: Z8IX2SC1OH)  
    BUTYLATED HYDROXYTOLUENE (UNII: 1P9D0Z171K)  
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    MICA (UNII: V8A1AW0880)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    FERRIC OXIDE YELLOW (UNII: EX438O2MRT)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:13734-126-30 1 in 1 CARTON
    1 12 g in 1 TRAY
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    OTC MONOGRAPH NOT FINAL part352 12/01/2012
    Labeler - NARS Cosmetics (837363571)
    Establishment
    Name Address ID/FEI Business Operations
    SHISEIDO AMERICA INC. 782677132 MANUFACTURE(13734-114, 13734-115, 13734-116, 13734-117, 13734-118, 13734-119, 13734-120, 13734-121, 13734-122, 13734-123, 13734-124, 13734-125, 13734-126) , ANALYSIS(13734-114, 13734-115, 13734-116, 13734-117, 13734-118, 13734-119, 13734-120, 13734-121, 13734-122, 13734-123, 13734-124, 13734-125, 13734-126)
    Establishment
    Name Address ID/FEI Business Operations
    Davlyn Industries Inc 624436254 MANUFACTURE(13734-114, 13734-115, 13734-116, 13734-117, 13734-118, 13734-119, 13734-120, 13734-121, 13734-122, 13734-123, 13734-124, 13734-125, 13734-126)